Location: Obesity and Metabolism Research
Project Number: 5306-51530-019-45-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Jan 1, 2009
End Date: Dec 31, 2011
The objective of the parent project is to identify metabolic and gene expression markers of assymptomatic cardiovascular disease, with the goal of providing early warning and improved clinical diagnostics, which will lead to improvements in intervention stratagies.
Round 1: ARS agrees to deliver quantitative analytical chemistry measurements of plasma (n=20) and atherosclerotic plaque (n=20) oxylipids and there distribution within plaque major lipid subclasses (i.e. cholesterol esters, triglycerides, and phospholipids) along with appropriate quality assurance/quality control samples. Findings will be summarized along with methods suitable for inclusion in peer reviewed publication. These samples will constitute a training set for the collaborators laboratory. Dr. Newman and affiliated laboratory experts will also consult on experimental design, data interpretation, and support manuscript preparation. Dr. Newman and his staff will remain blinded to all subject information and study groups. Final results will be shared without disclosing personal information. Dr. Newman will provide interpretive support for these results. Ancillary analyses of fatty acid analyses performed in the Newman lab will be available for use in larger efforts documenting variance in human lipid metabolism. Round 2: ARS agrees to provide laboratry access for the preparation of samples Dr. Wheelocks designees, to aquire quantitative measurements for oxylipins and endocannabinoids in sample extracts (n=70) on ARS instrumentation, to provide access to software to analyze the resulting data, and to oversee and critique the final quality assessment and interpretation of the data, and provide support in manuscript preparation.